GSK's $10.6 Billion Nuvalent Takeover Marks Largest Deal in 13 Years

GSK announced a definitive merger agreement on 9 June 2026 to acquire Nuvalent, a U.S. cancer drug developer, for $10.6 billion via tender offer. The deal is GSK's largest in over a decade, signaling a strategic concentration in specialty therapeutics following its 2022 separation from consumer health business Haleon. Nuvalent's pipeline targets lung cancer resistance mutations—a therapeutic gap in GSK's oncology franchise.